AKT1 and malignant colon neoplasm: Finally, the spotlight falls back on our compound that suppresses colon cancer cells in vitro and in vivo by targeting AKT (Fig. 9), suggesting that AKT represents an attractive target and CTD also can be developed as an AKT inhibitor for CRC chemotherapy.